Adrenal Crisis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Adrenal Crisis Market Outlook
Thelansis’s “Adrenal Crisis Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024
To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Adrenal Crisis treatment modalities options
for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and
China).
Adrenal
Crisis Overview
Adrenal
crisis (Addisonian crisis/acute adrenal insufficiency/bronze Addison disease)
as a profound impairment of general health and at least two of the following
conditions hypotension (systolic blood pressure 100mmHg), severe fatigue,
vomiting or nausea, hyperkalemia, hypoglycemia, and hyponatremia triggering
parenteral glucocorticoid administration. The risk factor associated with the
adrenal crisis is diabetes insipidus, diabetes mellitus (type 1 and type 2),
hypogonadism, adrenal hemorrhage, pregnancy, and polyglandular autoimmune
syndrome 1 and 2. An adrenal crisis occurs when there is adrenal insufficiency,
either primary or secondary. Primary adrenal crisis is characterized by high
ACTH from the destruction of the adrenal gland and low cortisol. Secondary
adrenal insufficiency is characterized by low cortisol and normal ACTH caused
by decreased ACTH secretion from the pituitary. The tertiary cause includes the
disruption of the hypothalamus, which affects the release of CRH and ACTH. In
adrenal insufficiency, patients experience an acute stress event. They cannot
adjust their usual dose of glucocorticoid therapy, causing their body cortisol
stores to rapidly deplete, leading to an adrenal crisis as patients cannot
produce cortisol.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment